27/01/2022 - 15:57

Resonance Health looks to China

27/01/2022 - 15:57

Bookmark

Save articles for future reference.

Resonance Health will enter the Chinese market after being contracted by Chinese pharmaceutical company Hangzhou Zede Pharma-Tech Co.

Resonance Health looks to China
Resonance Health to enter China's market with FerriScan. Photo: Hush Naidoo Jade

Resonance Health will enter the Chinese market after being contracted by Chinese pharmaceutical company Hangzhou Zede Pharma-Tech Co.  

Resonance’s FerriScan, a medical device used to measure liver-iron-concentration, will be used in Zede Pharma’s study to help develop a new treatment for iron overload in patients with thalassemia, a disease which impacts blood proteins.

Thalassemia is an inherited genetic blood disorder with an estimated 30-40 million people in China to carrying the genes.   

The contract was announced two days after Resonance Health was contracted for a clinical trial by VGI Health Technology for a potential new treatment of non-alcoholic steatohepatitis, a type of fatty liver disease. 

Resonance Health managing director Mitchell Wells said he was excited about the partnership with Zede Pharma.  

“I hope that our work with Zede Pharma is the beginning of a long and strong relationship with them and we look forward to helping them address the enormous challenge that thalassemia poses to patients in China and globally,” Mr Wells said. 

The study is expected to run for 14 months, beginning on March 1, 2022.  

Resonance Health shares closed today at 16.5 cents, up 3.1 per cent.

STANDING BY BUSINESS. TRUSTED BY BUSINESS.

Subscription Options